Core Viewpoint - Beyond Air, Inc. has terminated its proposed transaction with XTL Biopharmaceuticals regarding its NeuroNOS subsidiary, which was initially announced in January 2026 [1][2]. Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide to enhance patient care, particularly in respiratory illnesses, neurological disorders, and solid tumors [4]. - The company has received FDA approval and CE Mark for its LungFit PH system, aimed at treating neonates with hypoxic respiratory failure, and is advancing other LungFit systems in clinical trials for severe lung infections [4]. NeuroNOS Overview - NeuroNOS is dedicated to developing innovative treatments for neurodevelopmental and neurodegenerative disorders, utilizing small molecules that can cross the blood-brain barrier to regulate nitric oxide levels in the brain [5]. - Preclinical studies indicate elevated nitric oxide levels in children with Autism Spectrum Disorder and adults with brain-related diseases, highlighting the importance of managing nitric oxide for normal brain function [5]. Future Plans - Despite the termination of the transaction, Beyond Air remains committed to maximizing the value of the NeuroNOS platform and is exploring strategic alternatives for it while continuing to advance its core nitric oxide platform and LungFit programs [3].